<DOC>
	<DOCNO>NCT02426021</DOCNO>
	<brief_summary>The objective study investigate safety , pharmacokinetics , pharmacodynamic effect single dose MLN1202 healthy Japanese male adult .</brief_summary>
	<brief_title>Phase 1 Single Subcutaneous Dose Study MLN1202</brief_title>
	<detailed_description>This single dose , phase 1 study healthy Japanese Caucasian male adult . Japanese subject assign Cohort J1 ( dose 75 mg ) , Cohort J2 ( 105 mg ) , Cohort J3 ( 150 mg ) , Cohort J4 ( 450 mg ) randomize , double-blind , placebo-controlled manner , Caucasian subject Cohort C1 ( dose 75 mg ) Cohort C2 ( 150 mg ) open-label manner . Takeda make business decision terminate study due portfolio re-prioritization . There safety efficacy concern .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant sign date write informed consent form ( ICF ) prior initiation study procedure . 3 . The participant healthy adult man define Japanese ( parent grandparent participant Japanese ) Caucasian ( parent grandparent participant Caucasian ) . 4 . The participant 20 45 year age time informed consent . 5 . The participant body weight least 50 kg body mass index ( BMI ) 18.5 25.0 kg /m2 participant Japanese 18.5 30.0 kg /m2 participant Caucasian time screen baseline examination . 6 . A male participant sexually active female partner childbearing potential receive contraceptive therapy agree use adequate contraception time inform consent 12 week ( 84 day ) administration study drug . 1 . The participant receive investigational compound within 16 week ( 112 day ) prior administration study drug . 2 . The participant previously receive agent contain MLN1202 , monoclonal antibody monoclonal antibody fragment . 3 . The participant vaccinate within 4 week ( 28 day ) prior administration study drug planning vaccinate study period . 4 . The participant study site employee immediate family member employee , may consent duress . 5 . The participant poorlycontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , endocrine disease , hemorrhagic disorder abnormality may impact ability participant participate potentially confound study result . 6 . The participant recurrent serious poorlycontrolled infection consider difficulty participate study investigator . 7 . The participant history hypersensitivity allergy MLN1202 additive contain MLN1202 preparation . 8 . The participant history hypersensitivity allergies monoclonal antibody MLN1202 . 9 . The participant positive result urine drug test screen . 10 . The participant history drug abuse ( define illicit drug use ) history alcohol dependence within 2 year prior study visit screen unwilling agree abstain alcohol drug throughout study period . 11 . The participant require excluded medication food product list Excluded Medications Dietary Products ( see section 7.3 ) study period . 12 . The participant intend donate sperm study period period 12 week ( 84 day ) administration study drug . 13 . The participant history cancer . 14 . The participant , suspect , history active tuberculosis latent tuberculosis infection . 15 . The participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis B virus antibody ( hepatitis B surface antibody [ HBsAb ] / hepatitis B core antibody [ HBcAb ] ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen , serological reaction syphilis screen . This include participant positive test result HBsAb due HBV vaccination . 16 . The participant use nicotinecontaining product ( cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum , etc . ) within 4 week ( 28 day ) prior administration study drug . 17 . The participant poor peripheral venous access . 18 . The participant undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior administration study drug . 19 . The participant undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior administration study drug . 20 . The participant undergone blood component collection within 2 week ( 14 day ) prior administration study drug . 21 . The participant clinically significant electrocardiographic ( ECG ) abnormality time screen baseline examination . 22 . The participant abnormal laboratory value suggest clinically significant underlying disease , participant follow lab abnormality time screen baseline examination : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 Ã— upper limit normal , differential white blood count ( monocyte ) &lt; low limit normal . The following criterion evaluate laboratory test screen : insulin ( fast ) , parathyroid hormone ( PTH ) ( intact ) . 23 . The participant systolic blood pressure &lt; 80 mmHg diastolic blood pressure &lt; 45 mmHg , systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg time screening , baseline examination examination prior administration study drug . 24 . The participant receiving treatment wound , opinion investigator , unsuitable participate study . 25 . The participant schedule undergo surgery within 12 week ( 84 day ) administration study drug . 26 . In opinion investigator , participant unlikely comply protocol unsuitable reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>